Clinical significance of phospholipase A2 group IIA (PLA2G2A) expression in primary resected esophageal squamous cell carcinoma

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 6, 2013, Pages 752-757

  Ren, P ^a   Zhang, J G ^a   Xiu, L ^a   Yu, Z T ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Phospholipase A2 group IIA; Prognosis

Indexed keywords

PHOSPHOLIPASE A2 GROUP II;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84878579068     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. KAMANGAR F, DORES GM, ANDERSON WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. XING D, TAN W, LIN D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population. Oncol Rep 2003; 10: 1615-1623.
3. HIYAMA T, YOSHIHARA M, TANAKA S, CHAYAMA K. Genetic polymorphisms and esophageal cancer risk. Int J Cancer 2007; 121: 1643-1658.
4. SHAPPELL SB, OLSON SJ, HANNAH SE, MANNING S, ROBERTS RL, MASUMORI N, JISAKA M, BOEGLIN WE, VADER V, DAVE DS, SHOOK MF, THOMAS TZ, FUNK CD, BRASH AR, MATUSIK RJ. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 2003; 63: 2256-2267.
5. REILLY MP, LAWSON JA, FITZGERALD GA. Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. J Nutr 1998; 128(2 Suppl): 434S-438S.
6. SIX DA, DENNIS EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 2000; 1488: 1-19.
7. FIJNEMAN RJ, CORMIER RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci 2008; 13: 4144-4174.
8. MOUNIER CM, WENDUM D, GREENSPAN E, FLÉJOU JF, ROSENBERG DW, LAMBEAU G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer 2008; 98: 587-595.
9. AVORANTA T, SUNDSTRÖM J, KORKEILA E, SYRJÄNEN K, PYRHÖNEN S, LAINE J. The expression and distribution 757 Clinical significance of PLA2G2A expression in primary resected ESCC of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch 2010; 457: 659-667.
10. XING XF, LI H, ZHONG XY, ZHANG LH, WANG XH, LIU YQ, JIA SQ, SHI T, NIU ZJ, PENG Y, DU H, ZHANG GG, HU Y, LU AP, LI JY, CHEN S, JI JF. Phospholipase A2 group IIA expression correlates with prolonged survival in gastric cancer. Histopathology 2011; 59: 198-206.
11. KASHIWAGI M, FRIESS H, UHL W, BERBERAT P, ABOUSHADY M, MARTIGNONI M, ANGHELACOPOULOS SE, ZIMMERMANN A, BÜCHLER MW. Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis. Gut 1999; 45: 605-612.
12. LEUNG SY, CHEN X, CHU KM, YUEN ST, MATHY J, JI J, CHAN AS, LI R, LAW S, TROYANSKAYA OG, TU IP, WONG J, SO S, BOTSTEIN D, BROWN PO. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002; 99: 16203-16208.
13. DONG Z, LIU Y, SCOTT KF, LEVIN L, GAITONDE K, BRACKEN RB, BURKE B, ZHAI QJ, WANG J, OLEKSOWICZ L, LU S. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis 2010; 131: 1948-1955.
14. KUPERT E, ANDERSON M, LIU Y, SUCCOP P, LEVIN L, WANG J, WIKENHEISER-BROKAMP K, CHEN P, PINNEY SM, MACDONALD T, DONG Z, STARNES S, LU S. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer 2011; 11: 513.
15. MAUCHLEY D, MENG X, JOHNSON T, FULLERTON DA, WEYANT MJ. Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A(2). J Thorac Cardiovasc Surg 2010; 139: 591-599.
16. SOBIN LH, FLEMING ID. TNM classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804.
17. BUHMEIDA A, BENDARDAF R, HILSKA M, LAINE J, COLLAN Y, LAATO M, SYRJÄNEN K, PYRHÖNEN S. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol 2009; 20: 1230-1235.
18. JIANG J, NEUBAUER BL, GRAFF JR, CHEDID M, THOMAS JE, ROEHM NW, ZHANG S, ECKERT GJ, KOCH MO, EBLE JN, CHENG L. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002; 160: 667-671.
19. GRAFF JR, KONICEK BW, DEDDENS JA, CHEDID M, HURST BM, COLLIGAN B, NEUBAUER BL, CARTER HW, CARTER JH. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001; 7: 3857-3861.
20. BIRTS CN, BARTON CH, WILTON DC. Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem Sci 2010; 35: 28-35.